TAK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Takeda Pharmaceutical Co Ltd (TAK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, recent analyst upgrade, and stable trading sentiment make it a solid choice. While technical indicators show a neutral to slightly bearish trend in the short term, the long-term growth potential and positive financial metrics outweigh these concerns.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 32.605, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level of 17.739, with resistance at 18.671. Short-term technicals are neutral to slightly bearish.
Analyst upgrade by Bernstein with a significant price target increase due to cost-cutting measures and pipeline de-risking events.
Strong financial performance in Q3 2026, with revenue, net income, EPS, and gross margin showing significant YoY growth.
No recent significant insider or hedge fund trading activity.
Technical indicators suggest short-term bearish momentum.
In Q3 2026, Takeda reported a 4.16% YoY increase in revenue, a 335.66% YoY increase in net income, and a 337.08% YoY increase in EPS. Gross margin improved by 5.94% YoY to 54.91%, showcasing strong financial growth and profitability.
Bernstein upgraded Takeda to Outperform from Market Perform with a price target of 6,900 yen, up from 5,100 yen, citing bold cost cuts and pipeline de-risking events.
